OBJECTIVE: We assessed associations between physical activity and lung function, and its decline, in the prospective population-based European Community Respiratory Health Survey cohort. METHODS: FEV1 and FVC were measured in 3912 participants at 27-57 years and 39-67 years (mean time between examinations=11.1 years). Physical activity frequency and duration were assessed using questionnaires and used to identify active individuals (physical activity >/=2 times and >/=1 hour per week) at each examination. Adjusted mixed linear regression models assessed associations of regular physical activity with FEV1 and FVC. RESULTS: Physical activity frequency and duration increased over the study period. In adjusted models, active individuals at the first examination had higher FEV1 (43.6 mL (95% CI 12.0 to 75.1)) and FVC (53.9 mL (95% CI 17.8 to 89.9)) at both examinations than their non-active counterparts. These associations appeared restricted to current smokers. In the whole population, FEV1 and FVC were higher among those who changed from inactive to active during the follow-up (38.0 mL (95% CI 15.8 to 60.3) and 54.2 mL (95% CI 25.1 to 83.3), respectively) and who were consistently active, compared with those consistently non-active. No associations were found for lung function decline. CONCLUSION: Leisure-time vigorous physical activity was associated with higher FEV1 and FVC over a 10-year period among current smokers, but not with FEV1 and FVC decline.
- Fuertes, E.
- Carsin, A. E.
- Anto, J. M.
- Bono, R.
- Corsico, A. G.
- Demoly, P.
- Gislason, T.
- Gullon, J. A.
- Janson, C.
- Jarvis, D.
- Heinrich, J.
- Holm, M.
- Leynaert, B.
- Marcon, A.
- Martinez-Moratalla, J.
- Nowak, D.
- Pascual Erquicia, S.
- Probst-Hensch, N. M.
- Raherison, C.
- Raza, W.
- Gomez Real, F.
- Russell, M.
- Sanchez-Ramos, J. L.
- Weyler, J.
- Garcia Aymerich, J.
Keywords
- adults
- cohort
- forced expiratory volume in one second
- forced vital capacity
- physical activity
- smoking
- Circassia, Chiesi, Thermofisher Scientific and Menarini, and AGC reports grants
- from Chiesi Farmaceutici and from GlaxoSmithKline Italy, during the conduct of
- the study. Other authors declare no competing interests related to this work.